NCT00413322 - Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

March 31, 2008

Study Completion Date

June 30, 2008

Conditions

Tumor

Interventions

DRUG

belinostat

300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1

DRUG

5-Fluorouracil (5-FU)

250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.

Trial Locations (3)

85259

Mayo Clinic Arizona, Scottsdale

68198-7680

University of Nebraska, Omaha

03801

Portsmouth Regional Hospital Hematology/Oncology Clinic, Portsmouth